Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi and Lilly Collaborate on China Development of Cardiovascular Drug

publication date: Nov 11, 2015
WuXi PharmaTech and Eli Lilly will collaborate on China development of a novel, once-daily oral agent, discovered by Lilly and aimed at alleviating cardiovascular risk in patients with dyslipidemia. The drug candidate is designed to reduce cardiovascular events in patients with elevated LDL cholesterol and triglycerides who are at risk for heart attacks or strokes. WuXi will be responsible for regulatory, development and manufacturing activities in China, while Lilly will market the drug. Both companies will invest in the project. More details....

Stock Symbols: (NYSE: WX) (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital